Pilot study supports broader research on psilocybin for anorexia nervosa

Anorexia nervosa, a potentially fatal eating disorder, has few effective treatments. Researchers enrolled 21 adult women with the disorder in a pilot study involving three dosing sessions with COMP360, the proprietary synthetic psilocybin developed by Compass Pathways. The three sessions took place over 6 weeks in a fixed order: 1 mg, 25 mg, and 25 mg. Participants in the single-blind study also received talk therapy, and adverse events were monitored. The primary outcomes were measured by the Eating Disorder Examination (EDE) Interview and Readiness and Motivation Questionnaire (RMQ) precontemplation scores. The EDE was measured at the 6-week final visit, the 3-month follow-up, and the 6-month follow-up; the RMQ outcomes were scored at the 6-week final visit and compared between dosing days. At 12 months, the participants were followed up remotely. Relative to baseline, participants showed significant improvements in EDE scores and RMQ scores. The most common adverse events were headache, nausea, and dizziness; one participant made two suicide attempts within the 6–12-month follow-up period. The investigators concluded that their findings provide preliminary support for the feasibility, safety, and potential efficacy of psilocybin in treating adults with anorexia nervosa. Douglass, H. M., Spriggs, M. J., Godfrey, K., et al. (2026, Jul 8). Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry, 1–9. https://doi.org/10.1192/bjp.2026.10687 Online ahead of print.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-11-14
DOI
https://doi.org/10.1002/pu.31522
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pilot study supports broader research on psilocybin for anorexia nervosa

The Brown University Psychopharmacology Update
Psychedelics and Drug Studies
article

Pilot study supports broader research on psilocybin for anorexia nervosa

article en

Abstract

Anorexia nervosa, a potentially fatal eating disorder, has few effective treatments. Researchers enrolled 21 adult women with the disorder in a pilot study involving three dosing sessions with COMP360, the proprietary synthetic psilocybin developed by Compass Pathways. The three sessions took place over 6 weeks in a fixed order: 1 mg, 25 mg, and 25 mg. Participants in the single-blind study also received talk therapy, and adverse events were monitored. The primary outcomes were measured by the Eating Disorder Examination (EDE) Interview and Readiness and Motivation Questionnaire (RMQ) precontemplation scores. The EDE was measured at the 6-week final visit, the 3-month follow-up, and the 6-month follow-up; the RMQ outcomes were scored at the 6-week final visit and compared between dosing days. At 12 months, the participants were followed up remotely. Relative to baseline, participants showed significant improvements in EDE scores and RMQ scores. The most common adverse events were headache, nausea, and dizziness; one participant made two suicide attempts within the 6–12-month follow-up period. The investigators concluded that their findings provide preliminary support for the feasibility, safety, and potential efficacy of psilocybin in treating adults with anorexia nervosa. Douglass, H. M., Spriggs, M. J., Godfrey, K., et al. (2026, Jul 8). Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry, 1–9. https://doi.org/10.1192/bjp.2026.10687 Online ahead of print.

The Brown University Psychopharmacology UpdateVol. 37(12)
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon